GPX vs. APEI: Which School Stock Investors Should Keep Tabs on?
Zacks Investment Research | Sep 20, 2021 01:38AM ET
The Zacks VGM Score of A.
Shares of GP Strategies have gained 74.1% in the year-to-date period against American Public’s 12.7% fall. Nonetheless, both stocks have outperformed the industry’s 65.3% decrease in the same period.
Thus, GP Strategies is a clear winner in terms of earnings growth prospects and share price performance.
A Look at the Stocks’ Profitability & Valuation/h3
Return on Equity in the trailing 12 months for GP Strategies is 9.1% compared with American Public and the industry’s 5.2% and 6.5%, respectively. GP Strategies provides impressive returns to investors than American Public and the industry.
The trailing 12-month price-to-earnings multiple for GP Strategies and American Public is 18.49 and 22.74, respectively, compared with the industry’s 9.1. American Public’s shares are a bit costlier than GP Strategies and the industry.
Our Take/h3
GP Strategies certainly has an edge over American Public in terms of stock performance, expected earnings growth for 2021, return and valuation. Nonetheless, both companies remain optimistic about the overall industry growth trends, given solid demand for online education and professional courses, offsetting expansion-related higher costs and expenses.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.